北京商报讯（记者 丁宁）10月15日晚间，海尔生物（688139）发布公告称，10月15日，公司收到青岛 久实投资管理有限公司（代表"久实优选1号私募证券投资基金"，以下简称"久实优选1号"）《青岛海尔 生物医疗股份有限公司简式权益变动报告书》，基于对公司未来发展前景的信心和对公司长期投资价值 的认可，久实优选1号于2024年8月14日至2025年10月14日通过二级市场集中竞价和大宗交易方式增持公 司股份1589.79万股，占公司总股本的5%。 公告显示，本次权益变动后，久实优选1号拥有权益的股份数量占海尔生物总股本的比例为5%。 ...

格隆汇10月15日丨海尔生物(688139.SH)公布,基于对公司未来发展前景的信心和对公司长期投资价值的认可,久实优选1号于2024年8月14日至2025年10月14日通过二级市场集中竞价和大宗 本次权益变动属增持，资金来源为久实优选 1 号自有资金，不触及要约收购。 ...

证券代码：688139 证券简称：海尔生物 公告编号：2025-047 青岛海尔生物医疗股份有限公司 关于股东增持股份达到 5%的权益变动提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示 2 二、本次权益变动前后，信息披露义务人持有公司股份变动情况 名称 股份种类 本次权益变动前持有股 份情况 本次权益变动后持有 股份情况 久实优 选1号 股数（股） 占总 股本 比例 （%） 股数（股） 占总 股本 比例 （%） 人民币普通股 15,878,909 4.99 15,897,909 5.00 本次权益变动后青岛久实投资管理有限公司-久实优选 1 号私募证券投 资基金拥有权益的股份数量及占青岛海尔生物医疗股份有限公司（以下简称"海 尔生物"，"公司"）总股本的比例为 5%。 本次权益变动不会使公司控股股东、实际控制人发生变化。 一、本次权益变动基本情况 2025 年 10 月 15 日，公司收到青岛久实投资管理有限公司（代表"久实优 选 1 号私募证券投资基金"，以下简称"久实优选 1 号"或"信息披 ...

青岛海尔生物医疗股份有限公司 简式权益变动报告书 签署日期：2025年10月15日 上市公司名称： 青岛海尔生物医疗股份有限公司 股票上市地点： 上海证券交易所 股票简称： 海尔生物 股票代码： 688139.SH 信息披露义务人： 青岛久实投资管理有限公司（代表"久实优选1号私募 证券投资基金"） 基金备案编号 SJD567 住所： 青岛市市南区香港西路48号海天中心T2 通讯地址： 青岛市市南区香港西路48号海天中心T2 股份变动性质： 股份增加，成为5%以上股东 信息披露义务人声明 一、本信息披露义务人根据《中华人民共和国证券法》（以下简称"《证券 法》"）《上市公司收购管理办法》（以下简称"《收购办法》"）《公开发行证 券公司信息披露内容与格式准则第 15 号——权益变动报告书》（以下简称 "《准则 15 号》"）等相关的法律、法规及规范性文件编写本报告书。 二、信息披露义务人签署本报告已获得必要的授权和批准，其履行亦不违 反信息披露义务人内部规则中的任何条款，或与之相冲突。 三、依据《证券法》《收购办法》《准则 15 号》规定，本报告书已全面覆 盖信息披露义务人在青岛海尔生物医疗股份有限公司（以下简 ...

海尔生物(688139.SH)公告称，久实优选1号私募证券投资基金通过二级市场集中竞价和大宗交易方式合 计增持公司股份15,897,909股，占公司总股本的5.00%，增持资金来源为自有资金。此次权益变动后， 久实优选1号成为公司持股5%以上的股东。 ...

格隆汇10月9日丨海尔生物(688139.SH)公布，截至2025年9月30日，公司通过上海证券交易所交易系统 以集中竞价交易方式累计回购公司股份252.95万股，占公司总股本的比例为0.7956%，回购成交的最高 价为34.69元/股，最低价为29.86元/股,支付的资金总额为人民币8211.86万元（不含交易费用）。 ...

| 回购方案首次披露日 | 2025/1/14 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 1 月 13 | 1 | 月 | 14 | 日~2026 | 年 | 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 2,529,477股 | | | | | | | | 累计已回购股数占总股本比例 | 0.7956% | | | | | | | | 累计已回购金额 | 82,118,554.17元 | | | | | | | | 实际回购价格区间 | 29.86元/股~34.69元/股 | | | | | | | 一、回购股份的基本情况 青岛海尔生物医疗股份有限公司（以下简称"公司"）于 2025 年 1 月 13 ...

Group 1 - The 92nd China International Medical Equipment Fair (Autumn CMEF) opened on September 26, attracting nearly 3,000 companies from around 20 countries and over 120,000 professional visitors [1] - Haier Biomedical showcased over 20 innovative products and solutions across four major industries: laboratory solutions, smart medication, blood technology, and low-temperature storage [1] - The company launched the first domestically approved ultra-low temperature storage box using deep green technology and introduced a new cloud series safety cabinet to enhance laboratory work experience [1][2] Group 2 - By the first half of 2025, new industries accounted for a significant portion of Haier Biomedical's revenue, with automation, cell culture, high-speed centrifugation, and intelligent systems achieving leading positions domestically and internationally [2] - The company presented its AI technology integration with life sciences and medical innovation, including the Edmond sample management solution for high-risk samples, enhancing safety and efficiency in high-level laboratories [2] - Haier Biomedical's overseas revenue grew by over 30% year-on-year in the first half of this year, with significant market share in 25 countries for its ultra-low temperature storage boxes, drug constant temperature boxes, and solar vaccine refrigeration boxes [3]

Core Insights - The article highlights the emergence of innovative companies in the life sciences sector, showcasing their disruptive technologies and products at the upcoming "2025 Life Science Innovation Instrument Investment Conference" [2][3]. Industry Overview - The life sciences industry is experiencing explosive innovation, driven by breakthroughs in basic science, industrial demand, national policy support, and financial capital influx. The integration of AI, automation, and multi-omics technologies is leading to a surge in innovative life science instruments [3]. Conference Highlights - Haier Biomedical will present its IoT-based smart laboratory and medical safety solutions, covering over 1,000 products across eight categories, aimed at providing reliable and traceable intelligent products for research institutions, hospitals, and universities [4]. - Yokogawa Electric will share its optical technology innovations and discuss long-term cooperation models with Chinese partners, showcasing its DualSpinDisk technology for 3D cell observation [4]. - Guangzhou Boda Boju will focus on practical solutions for cell counting challenges, addressing data accuracy, cost control, and high-throughput detection [5]. - Shanghai Xiaohai Turtle will introduce its single-tube ultra-multiplex digital PCR technology, which enhances detection efficiency and reduces costs across various applications [5]. - Sichuan Jialei Mei, a specialized enterprise, will present its core products in molecular detection and AI image recognition, emphasizing its applications in biosafety [6]. - Jiangsu Ruiming Bio will introduce a real-time single-cell multifunctional analyzer, providing powerful tools for drug screening and cell therapy research [6]. Conference Schedule - The conference will feature presentations from various companies, including Haier Biomedical, Yokogawa Electric, Guangzhou Boda Boju, Shanghai Xiaohai Turtle, Sichuan Jialei Mei, and Jiangsu Ruiming Bio, covering topics from channel cooperation to innovative technologies [8].

Core Viewpoint - The medical device export sector in China is experiencing growth, with a notable increase in revenue and profit among companies listed on the STAR Market, driven by innovation, international expansion, and strategic mergers and acquisitions [1][2][4]. Group 1: Market Performance - In the first half of 2025, China's medical device exports reached $24.1 billion, marking a 5.0% year-on-year increase and accounting for over 40% of total pharmaceutical product exports [1]. - STAR Market medical device companies reported a revenue growth of 9% and a net profit growth of 3% year-on-year, with second-quarter revenue and net profit showing quarter-on-quarter growth of 22% and 30%, respectively [1]. - Nearly 30% of STAR Market medical device companies have over 30% of their business coming from overseas [1]. Group 2: Innovation and Global Strategy - STAR Market medical device companies focus on high-value consumables and medical equipment, leveraging capital market support to build extensive global marketing networks [2]. - The industry has seen the emergence of several benchmark companies, with a total of approximately 18,000 invention patents held by STAR Market medical device firms [2]. - Notable innovations include the world's first branched aortic stent graft approved for market by Shanghai MicroPort Medical, and the FDA breakthrough designation for the self-expanding intracranial drug-coated stent system by Sinno Medical [2]. Group 3: International Expansion - Shanghai United Imaging Healthcare Co., Ltd. has increased its overseas revenue share from less than 10% at the time of listing to nearly 20% in the first half of 2025 [3]. - Haier Biomedical and Chongqing Mountain Outside Mountain Blood Purification Technology Co., Ltd. reported overseas revenue growth of 30% and 41%, respectively, in the first half of 2025 [3]. - The global expansion of domestic medical device companies is evident, with Haier Biomedical's products applied in over 150 countries and regions [3]. Group 4: Mergers and Acquisitions - The medical device industry is increasingly utilizing mergers and acquisitions to expand product lines and enhance technological capabilities, supported by policies such as "Merger and Acquisition Six Articles" and "STAR Market Eight Articles" [4]. - Shanghai Sanyou Medical Devices Co., Ltd. has successfully acquired the French orthopedic company Implanet, significantly boosting its overseas revenue [5]. - Shenzhen Huatai Medical Devices Co., Ltd. has improved its market penetration and product coverage following the introduction of Mindray Medical as a controlling shareholder [5]. Group 5: Policy Support and Future Outlook - The Chinese government has introduced numerous supportive policies aimed at fostering high-end innovation and quality development in the medical device sector [6]. - The industry is expected to transition from "product export" to "technology output" and from "landing" to "local integration," positioning itself for higher value within the global value chain [6].